As the global pet population surpasses one billion (according to HealthforAnimals), awareness of pet health management continues to grow. According to a Grand View Research report, the global pet pharmaceutical market reached approximately $46 billion in 2024 and is projected to exceed $60 billion by 2030, with a compound annual growth rate exceeding 6.5%. This growth is primarily driven by multiple factors, including the humanization of pets, the increase in aging pets, and the widespread adoption of preventive medicine.
Upgrading the structure of pet medicines: from treatment to prevention and nutrition
Over the past decade, the pet pharmaceutical market has gradually expanded from "disease treatment" to the trinity of "prevention + nutrition + functional care".
Preventive medicines: Deworming, flea control, and vaccines remain the top-selling pet medicines globally. Approximately 70% of pets in European and American households receive regular deworming medication annually.
Therapeutic drugs: As the population of pets ages, the demand for drugs for chronic diseases such as arthritis, skin diseases, and gastrointestinal diseases has increased significantly.
Functional nutritional products: Products that combine health benefits with medicinal properties, such as probiotics, vitamins, and joint nutrients, are growing at an annual rate of more than 15% in the Asian and European markets.
This structural change provides Chinese pet product export companies with a new direction for innovation - developing "safe, natural, and functional" pet medicines and care products.
International market trends: Safety and sustainability become core competitiveness
The global pet pharmaceutical market presents the following three major trends:
Safety and compliance: The European and American markets have increasingly stringent regulations on pet medicines, requiring compliance with certification standards such as FDA and EMA.
Natural and environmentally friendly materials: Consumers tend to choose plant extracts, low-irritation formulas and biodegradable packaging.
Regionally differentiated demands: The European market focuses on functionality and regulations, the Asian market focuses on practicality and cost-effectiveness, and the American market emphasizes animal welfare and product innovation.
According to Statista, global pet health spending will exceed US$200 billion by 2028. China, India, and Southeast Asia will be the fastest-growing regions for pharmaceutical and healthcare product exports.
The rise of the pet pharmaceutical industry reflects the evolving global pet care landscape.
Linyi Xinghong Trading Co., Ltd., a professional pet product exporter, prioritizes health, safety, and environmental protection, actively monitoring global trends in pet pharmaceuticals and care. We are committed to providing higher-quality health solutions for pets worldwide, leveraging the power of Made in China to safeguard the well-being and safety of pets worldwide.
